Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor
作者:Lyamin Z. Bendjeddou、Nadège Loaëc、Benoît Villiers、Eric Prina、Gerald F. Späth、Hervé Galons、Laurent Meijer、Nassima Oumata
DOI:10.1016/j.ejmech.2016.09.064
日期:2017.1
3,6-Disubstituted imidazo[1,2-b]pyridazine derivatives were synthesized to identify new inhibitors of various eukaryotic kinases, including mammalian and protozoan kinases. Among the imidazo[1,2-b]pyridazines tested as kinase inhibitors, several derivatives were selective for DYRKs and CLKs, with IC50 < 100 nM. The characterization of the kinome of several parasites, such as Plasmodium and Leishmania
合成了3,6-二取代的咪唑并[1,2-b]哒嗪衍生物,以鉴定各种真核激酶的新抑制剂,包括哺乳动物和原生动物激酶。在作为激酶抑制剂测试的咪唑并[1,2-b]哒嗪中,几种衍生物对DYRK和CLK具有选择性,IC 50 <100 nM。几种疟原虫和利什曼原虫等寄生虫的激酶组的特征表明,这些寄生虫的蛋白激酶与宿主的蛋白激酶之间存在着巨大的差异。这使我们研究了所制备化合物针对11种寄生激酶的活性。3,6-二取代的咪唑并[1,2-b]哒嗪显示出对恶性疟原虫CLK1(PfCLK1)。发现化合物20a是对CLK1(IC 50 = 82 nM),CLK4(IC 50 = 44 nM),DYRK1A(IC 50 = 50 nM)和Pf CLK1(IC 50 = 32 nM)最具选择性的产物。还测试了该化合物对亚马逊利什曼原虫的抵抗力。通过使用成神经母细胞瘤细胞系进行的活力分析判断,数种化合物在较高浓